Caprolactam (aminocaproic lactam, 2-oxohexamethylenimine, CAS No. 105-60-2), the monomer used in the production of nylon-6, was selected and testing initiated by the Carcinogenesis Testing Program, National Cancer Institute (now part of the National Institute of Environmental Health Sciences/National Toxicology Program) because nearly one billion pounds per year are produced, because of the widespread use in food packaging materials and clothing, and because no carcinogenicity studies had been done (1) .
Nylon 6 resins/fibers are used extensively in carpets, knit fabrics, hosiery, thread, hairbrushes, replacement parts for automobiles and machinery, flotation devices, and food packaging. Highly soluble in water, caprolactam reportedly leaches from clothing made from polyamide fibers when soaked in simulated perspiration (2). Ferguson and Wheeler (3) reported irritation of the skin, eyes, nose, and throat in workers occupationally exposed to caprolactam dust or vapor at concentrations ranging from 10 to 100 ppm. All animals that died during the study or that were killed at the end of the exposure period were subjected to a gross necropsy and a complete histopathological examination. Statistical analyses comparing survival and numbers of animals with specific site tumors were done with trend tests and pairwise comparisons (4-7). The study design conformed to the NCI Guidelines for carcinogen bioassay (8) .
Methods

Results
Throughout the bioassay, mean body weight gains for treated rats and mice decreased (and dose related) in comparison to controls. For rats, feed consumption by high dose males and females was 70-80% of that for controls; no difference was observed for mice. Survival was comparable among all groups.
The incidences of caprolactam-treated animals with specific site tumors did not differ significantly from those diagnosed in controls. Tables 1 (rats) and 2 'Two other male rats had neoplastic nodules.
bOne other male rat had a thyroid C-cell carcinoma.
cOne other female rat had a thyroid follicular-cell adenoma. effects interpreted as being unrelated to the administration of caprolactam included the negative trends calculated for papillary adenocarcinomas of the mammary gland in female rats (4/49, 1/50, 0/50), for subcutaneous fibromas in male rats (5/50, 3/50, 0/50), for lung alveolar/bronchiolar adenomas in female mice (3/50, 0/49, 0/50), and for leukemias/lymphomas of the hematopoietic system in female mice (4/50, 2/49, 0/50). Because no evidence of neoplastic or nonneoplastic lesions could be related to dietary administration of caprolactam, under the conditions of this bioassay caprolactam was not carcinogenic for F344 rats or B6C3F1 mice of either sex (9) .
